CASL's HepatoSite - our online learning portal - is now online, visit Member Portal to Learn More

Educational Resources

CASL webinars and other enduring educational resources can now be found in the HepatoSite, our online learning portal.

CASL members can access HepatoSite via the link in the ‘Members Only‘ area of the website.

 

Non-members may purchase access to select content – click here to create an account and browse the catalogue of resources. 

 

 


Health Canada Resources on Drug Safety:

  • Summary Safety Review Information Page 
    • January 2021: Health Canada Marketed Health Products Directorate correspondence regarding Sofosbuvir-containing products: Assessing the Potential Risk of Severe Cutaneous Adverse Reactions (SCAR) [English] [French]
    • December 2020: Health Canada Marketed Health Products Directorate correspondence regarding direct-acting antivirals (DAAs) containing a protease-inhibitor: risks of hepatic decompensation and hepatic failure [English] [French]
    • August 2019: FDA News Release regarding the rare occurrence of serious liver injury in patients who use certain hepatitis c medicines

 


The CIHR Institute of Nutrition, Metabolism and Diabetes INMD Connections newsletters:


Primary Care Treatment and Referral Pathways:


Please visit the following websites for resources on Hepatopulmonary Syndrome: